SRI International, a Menlo Park, Calif.-based nonprofit research and development organization, has been awarded a $6.3 million contract for brain imaging research by the National Institute of Mental Health.
The contract will fund SRI to conduct preclinical safety studies of novel ligands that will be used for brain imaging research and clinical applications. Ligands are types of molecules that can be used to perform brain imaging with PET, SPECT and MRI.
The preclinical studies will help determine the safety, optimal dosage and form for delivery of imaging agents and medications for the treatment of mental disorders, according to the firm. Toxicology and safety data generated from this program may be used to support investigational new drug applications to the FDA, it said.